• Pharma and Biotech Daily: AstraZeneca's Shift, FDA Concerns, Novartis CEO Speaks Out, Pfizer's Savings, and More

  • Apr 30 2025
  • Duración: 1 m
  • Podcast

Pharma and Biotech Daily: AstraZeneca's Shift, FDA Concerns, Novartis CEO Speaks Out, Pfizer's Savings, and More

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. AstraZeneca has decided to abandon its neuroscience research and focus on weight loss and immunology, following recent discontinuations in Alzheimer's and migraine research. FDA experts are urging Commissioner Makary to resist politicization of the agency. Novartis CEO dismisses tariffs but warns against Trump's pricing controls. Pfizer announces $1.7 billion in cost savings, including a revamp of its R&D organization. Trilink Biotechnologies introduces custom sets of mRNA for screening studies. Other news includes Steminent showcasing therapy for spinocerebellar ataxia, Regeneron's shares tumbling, and ABEONA receiving FDA approval for a gene therapy for a rare skin disease. In summary, AstraZeneca shifts focus, FDA concerns arise, Novartis CEO speaks out, Pfizer announces cost savings, Trilink Biotechnologies introduces new product, Steminent showcases therapy, Regeneron's shares tumble, and ABEONA receives FDA approval.
    Más Menos
Más Menos
adbl_web_global_use_to_activate_webcro805_stickypopup

Lo que los oyentes dicen sobre Pharma and Biotech Daily: AstraZeneca's Shift, FDA Concerns, Novartis CEO Speaks Out, Pfizer's Savings, and More

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles